-1-

	SEQUENCE LISTING													
•														
	<110> Bayer AG, BHC													
	<120> Diagnostics and Therapeutics for Diseases Associated with Kallikre	i												
5	9 (KLK9)													
	<130> Le A 36 871													
	<160> 5													
	<170> PatentIn version 3.1													
	<210> 1													
10 .	<211> 753													
	<212> DNA													
	<213> Homo sapiens													
	<400> 1													
	atgaagetgg gaeteetetg tgetetgete tetetgetgg cagggeatgg etgggeagae 60													
15	accegtgeca teggggeega ggaatgtege eccaacteee ageettggea ggeeggeete 120													
	ttccacctta ctcggctctt ctgtggggcg accctcatca gtgaccgctg gctgctcaca 180													
	gctgcccact gccgcaagcc gtatctgtgg gtccgccttg gagagcacca cctctggaaa 240													
	tgggagggtc cggagcagct gttccgggtt acggacttct tcccccaccc tggcttcaac 300													
	aaggacetca gegecaatga ecacaatgat gacateatge tgateegeet geecaggeag 360													
20	gcacgtetga gtcctgetgt geageceete aaceteagee agacetgtgt etcceceagge 420													
	atgeagtgte teateteagg etggggggee gtgteeagee ceaaggeget gttteeagte 480													
•	acactgoagt gtgccaacat cagcatcotg gagaacaaac totgtcactg ggcataccot 540													
	ggacacatct cggacagcat gctctgtgcg ggcctgtggg aggggggccg aggttcctgc 600													
	cagggtgact ctgggggccc cctggtttgc aatggaacct tggcaggcgt ggtgtctggg 660													
25	ggtgctgagc cctgctccag accccggcgc cccgcagtct acaccagcgt atgccactac 720													
	cttgactgga tccaagaaat catggagaac tga 753													
	<210> 2													
	<211> 250													
	<212> PRT													
30	<213> Homo sapiens													
	<400> 2													
	Met Lys Leu Gly Leu Leu Cys Ala Leu Leu Ser Leu Leu Ala Gly His													
	1 5 10 15													
	Gly Trp Ala Asp Thr Arg Ala Ile Gly Ala Glu Glu Cys Arg Pro Asn													
35	20 25 30													
	Ser Gln Pro Trp Gln Ala Gly Leu Phe His Leu Thr Arg Leu Phe Cys													
	35 40 · 45													
	Gly Ala Thr Leu Ile Ser Asp Arg Trp Leu Leu Thr Ala Ala His Cys													
	50 55 60													
40	Arg Lys Pro Tyr Leu Trp Val Arg Leu Gly Glu His His Leu Trp Lys													
	65 70 75 80 ·													

Trp Glu Gly Pro Glu Gln Leu Phe Arg Val Thr Asp Phe Phe Pro His
85 90 95

-2- .

	Pro Gly	Phe		ГÀЗ	Asp	Гел	Ser		Asn	Авр	His	Asn		Asp	Ile		
			100	•	•			105					110				
	Met Leu	Ile	Arg	Feń	Pro	Arg	Gln	Ala	Arg	Leu	Ser	Pro	Ala	Val	Gln		
		115					120					125					
5	Pro Leu	Asn	Leu	Ser	Gln	Thr	Cys	Val	Ser	Pro	Gly	Met	Gln	Сла	Leu		
	130					135					140						
	Ile Ser	Gly	Trp	Gly	Ala	Val	Ser	Ser	Pro	Lys	Ala	Leu	Phe	Pro	Val		
	145				150					155					160		
	Thr Leu	Gln	Cys	Ala	Asn	Ile	Ser	Ile	Leu	Glu	Asn	Lys	Leu	Cys	His		
10				165					170					175			
	Trp. Ala	Tyr	Pro	Gly	His	Ile	Ser	Asp	Ser	Met	Leu	Cys	Ala	Gly	Leu		
	•		180					185					190				
	Trp Glu	Gly	Gly	Arg	Gly	Ser	Cys	Gln	Gly	Asp	Ser	Gly	Gly	Pro	Leu		
		195					200					205					
15	Val Cys	Asn	Gly	Thr	Leu	Ala	Gly	Val	Val	Ser	Gly	Gly	Ala	Glu	Pro		
	210)				215					220						•
	Cys Ser	Arg	Pro	Arg	Arg	Pro	Ala	Val	Tyr	Thr	Ser	Val	Сув	His	Tyr		
	225				230				_	235			-		240		
	Leu Asp	Trp	Ile	Gln	Glu	Ile	Met	Glu	Asn								
20	_	_		245					250							•	
-	<210>	3															
	<211>	19															
	<212>	DNA															
	<213>	arti	fici	al s	eđre	nce								•			
25	<220>				_												
	<223> forward primer																
	<400> 3																
	gegetgttte cagteacac															19	
	<210>	4															
30	<211>	21															
	<212>	DNA															-
	<213>	arti	fici	al s	eque	nce											
	<220>				_												
2.5	<223>		rse	prim	er							-					
35	<400> gcccagt	4 cgac	aqaq	tttq	tt c												21
	<210>	5		J													
	<211>	24		•													
	<212>	DNA								•							
40	<213>	arti	fici	al s	eđre	nce	•	•	•								
	<220>																
	<223>	prob	e			•											
	<400>	5															
	cagtgt	cca	acat	cago	at c	cta											24

WO 2005/021781 PCT/EP2004/009202

- 1/2 -

Fig. 1

SEQ ID NO: 1

ATGAAGCTGGGACTCCTCTGTGCTCTCTCTCTCTGCTGGCAGGGCAT GGCTGGGCAGACACCCGTGCCATCGGGGCCGAGGAATGTCGCCCCAAC TCCCAGCCTTGGCAGGCCGGCCTCTTCCACCTTACTCGGCTCTTCTGT GGGGCGACCCTCATCAGTGACCGCTGGCTGCTCACAGCTGCCCACTGC CGCAAGCCGTATCTGTGGGTCCGCCTTGGAGAGCACCACCTCTGGAAA TGGGAGGGTCCGGAGCAGCTGTTCCGGGTTACGGACTTCTTCCCCCAC CCTGGCTTCAACAAGGACCTCAGCGCCAATGACCACAATGATGACATC ATGCTGATCCGCCTGCCCAGGCAGGCACGTCTGAGTCCTGCTGTGCAG CCCCTCAACCTCAGCCAGACCTGTGTCTCCCCCAGGCATGCAGTGTCTC ATCTCAGGCTGGGGGCCGTGTCCAGCCCCAAGGCGCTGTTTCCAGTC ACACTGCAGTGTGCCAACATCAGCATCCTGGAGAACAACTCTGTCAC TGGGCATACCCTGGACACATCTCGGACAGCATGCTCTGTGCGGGCCTG TGGGAGGGGGCCGAGGTTCCTGCCAGGGTGACTCTGGGGGCCCCCTG GTTTGCAATGGAACCTTGGCAGCCGTGGTGTCTGGGGGTGCTGAGCCC TGCTCCAGACCCCGGCGCCCCGCAGTCTACACCAGCGTATGCCACTAC CTTGACTGGATCCAAGAAATCATGGAGAACTGA

WO 2005/021781 PCT/EP2004/009202

- 2/2 -

Fig. 2

SEQ ID NO: 2

MKLGLLCALLSLLAGHGWADTRAIGAEECRPNSQPWQAGLFHLTRLFC
GATLISDRWLLTAAHCRKPYLWVRLGEHHLWKWEGPEQLFRVTDFFPH
PGFNKDLSANDHNDDIMLIRLPRQARLSPAVQPLNLSQTCVSPGMQCL
ISGWGAVSSPKALFPVTLQCANISILENKLCHWAYPGHISDSMLCAGL
WEGGRGSCQGDSGGPLVCNGTLAGVVSGGAEPCSRPRRPAVYTSVCHY
LDWIQEIMEN

Fig. 3

SEQ ID NO: 3

5'-gcgctgtttccagtcacac-3'

Fig. 4

SEQ ID NO: 4

5'-gcccagtgacagagtttgttc-3'

Fig. 5

SEQ ID NO: 5

5'-cagtgtgccaacatcagcatcctg-3'